{
  "docId": "019de075-ab2a-73e5-980a-7d480707ba09",
  "docSlug": "340a1966b9939070959283ec1665bfbf",
  "documentTitle": "Kymera | Investor Presentation Deck | 60 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 33,
  "pageCount": 60,
  "prevPage": 32,
  "nextPage": 34,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-ab2a-73e5-980a-7d480707ba09/33",
  "deckHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09",
  "deckJsonHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09.json",
  "deckAnchorHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09#slide-33",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.84
      },
      "kind": "list",
      "text": "Results support advancing KT-474 into Phase 2 placebo-controlled trials, Sanofi expects to start Ph2 clinical trials in HS and AD in 4Q23",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "011d570c-7d42-4f15-97ea-af7752228c5f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.42
      },
      "kind": "list",
      "text": "Robust degradation of IRAK4 in blood and skin was associated with systemic anti-inflammatory effect in HS and AD patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1a394e8f-718f-4e07-b434-a809dbd7646c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.14
      },
      "kind": "list",
      "text": "KT-474 administered to HS and AD patients at 75 mg QD for 28 days shown to have safety, PK and PD comparable to healthy volunteers",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b2cf7e1-042e-46b1-8e82-2a3395de5331",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.7
      },
      "kind": "list",
      "text": "Data presented here validate IRAK4 degradation as a potential best in class mechanism in inflammatory diseases and its superior clinical potential over SMI",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8b6684d0-7992-4bc1-a079-455c479a43fe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.56
      },
      "kind": "list",
      "text": "Promising clinical activity observed in HS and AD exceeding benchmark placebo rates and comparing favorably to SOC biologics",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8e738313-75a9-4a8c-9cdb-e9a35cf05fe9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "list",
      "text": "Modest, non-adverse QTcF prolongation observed to spontaneously resolve back to baseline during final 2 weeks of dosing in HS and AD patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b3569cfb-71ab-4707-9549-a63b66a7eeb0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.18,
        "x": 0.41,
        "y": 0.04
      },
      "kind": "title",
      "text": "Part C Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d5f4326-beb8-4f5e-bc99-3195b3e3f6ea",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}